Development and Application of a Stable Isotope Dilution Analysis for the Quantitation of Advanced Glycation End Products of Creatinine in Biofluids of Type 2 Diabetic Patients and Healthy Volunteers

2013 ◽  
Vol 85 (5) ◽  
pp. 2961-2969 ◽  
Author(s):  
Christof Kunert ◽  
Thomas Skurk ◽  
Oliver Frank ◽  
Roman Lang ◽  
Hans Hauner ◽  
...  
Keyword(s):  
Isotope Dilution Analysis ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Stable Isotope Dilution Analysis ◽  
Stable Isotope Dilution ◽  
Glycation End Products ◽  
End Products ◽  
Type 2 Diabetic

scholarly journals Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease

Diabetes Care ◽  
2007 ◽  
Vol 30 (3) ◽  
pp. 670-676 ◽  
Author(s):  
A. Lapolla ◽  
F. Piarulli ◽  
G. Sartore ◽  
A. Ceriello ◽  
E. Ragazzi ◽  
...  
Keyword(s):  
Antioxidant Status ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Peripheral Artery ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease ◽  
Type 2 Diabetic

scholarly journals Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Anna Lados-Krupa ◽  
Malgorzata Konieczynska ◽  
Artur Chmiel ◽  
Anetta Undas
Keyword(s):  
Oxidative Stress ◽  
Disease Duration ◽  
Fibrin Clot ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Type 2 Diabetic

Aims. We sought to investigate whether enhanced oxidation contributes to unfavorable fibrin clot properties in patients with diabetes.Methods. We assessed plasma fibrin clot permeation (Ks, a measure of the pore size in fibrin networks) and clot lysis time induced by recombinant tissue plasminogen activator (CLT) in 163 consecutive type 2 diabetic patients (92 men and 71 women) aged 65 ± 8.8 years with a mean glycated hemoglobin (HbA1c) of 6.8%. We also measured oxidative stress markers, including nitrotyrosine, the soluble form of receptor for advanced glycation end products (sRAGE), 8-iso-prostaglandin F2α(8-iso-PGF2α), oxidized low-density lipoprotein (oxLDL), and advanced glycation end products (AGE).Results. There were inverse correlations betweenKsand nitrotyrosine, sRAGE, 8-iso-PGF2α, and oxLDL. CLT showed a positive correlation with oxLDL and nitrotyrosine but not with other oxidation markers. All these associations remained significant forKsafter adjustment for fibrinogen, disease duration, and HbA1c (allP<0.05), while oxLDL was the only independent predictor of CLT.Conclusions. Our study shows that enhanced oxidative stress adversely affects plasma fibrin clot properties in type 2 diabetic patients, regardless of disease duration and glycemia control.

scholarly journals Serum Fluorescence of Advanced Glycation End Products: A Potential Screening Tool to Distinguish Between Diabetic Patients with and without Microvascular Complications

2020 ◽  
Author(s):  
Sadaf Ali ◽  
Nivedita L Rao
Keyword(s):  
Diabetes Mellitus ◽  
Screening Tool ◽  
Microvascular Complications ◽  
Diabetic Patients ◽  
Advanced Glycation ◽  
Type 2 Diabetic Patients ◽  
Glycation End Products ◽  
End Products ◽  
Type 2 Diabetic

Introduction: Enhanced formation and accumulation of Fluorescent Advanced Glycation End products (F-AGEs) in diabetes mellitus have been linked to increased risk of developing the associated vascular complications. Aim: To evaluate the potential of serum fluorescence levels of F-AGEs as screening tools to distinguish between type 2 diabetic patients with and without microvascular complications such as retinopathy, neuropathy. Materials and Methods: This cross-sectional study was conducted between June 2016 and June 2017, included 95 type 2 diabetic patients with more than 1 year of diabetes duration. Fasting blood glucose, glycated haemoglobin and total protein levels were estimated by automated methods. Serum F-AGEs were estimated by using a simple spectrofluorometric method. Microvascular complications due to diabetes mellitus were studied in each patient from medical records data on fundus examination for retinopathy and touch, vibration sensation detection for neuropathy. Diabetic patients were categorised into two groups as those without microvascular complications and those with microvascular complications-retinopathy and neuropathy. Statistical tests used for comparisons between groups were chi-square test for gender distribution, independent t-test for other parameters and Pearson’s correlations. The p-value <0.05 indicated significant difference between variables. Results: Mean age of the population was 55.1±5.3 years. Diabetic patients with microvascular complications (n=26) in the form of retinopathy, neuropathy had significantly higher levels of serum F-AGEs with mean 7.4±1.8 AU/g protein compared with diabetic patients without complications with mean value 1.5±0.7 AU/g protein (p<0.01). Conclusion: Two categories of serum fluorescent AGE values, without overlap, could be distinguished between diabetic patients with and without complications. Measurement of serum F-AGEs products has the potential to emerge as a simple, valuable screening tool to distinguish between diabetic patients with and without microvascular complications.

Sign in / Sign up

Export Citation Format

Share Document